ArticleTransboundary and emerging diseases2026
Development of a Blocking ELISA for the Serological Diagnosis of Getah Virus.
Article in Transboundary and emerging diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of a Blocking ELISA for the Serological Diagnosis of Getah Virus.Transboundary and emerging diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Getah virus (GETV) is an emerging arbovirus that poses a growing threat to the swine industry because of its ability to infect pigs and other animals. However, the lack of an effective porcine GETV vaccine and commercially available diagnostic tools has hindered control efforts. In the study, we expressed the recombinant GETV E2 protein in a mammalian cell system to preserve its native conformation and antigenicity and generated monoclonal antibodies (mAbs) by immunizing mice with this protein. Using the GETV E2 protein and horseradish peroxidase (HRP)-labeled mAbs, we successfully established a rapid and specific blocking ELISA for the serological detection of GETV. The assay was comprehensively evaluated for specificity, reproducibility, and consistency with the reference immunofluorescence assay (IFA), demonstrating reliable diagnostic performance. In a clinical evaluation involving 462 samples, the assay showed a positive rate of 12.121%, confirming its practical applicability. This novel blocking ELISA provides a valuable tool for vaccine development and epidemiological investigations, contributing to more effective strategies for GETV control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.